RPX-602

RPX-602 is a reformulated intravenous formulation of the tetracycline-class antibiotic minocycline, developed as an improved version of Minocin IV for the treatment of serious Gram-negative infections in hospitalized patients. It is based on minocycline hydrochloride and uses a magnesium-based formulation to enhance stability and solubility compared with earlier intravenous products. As a semisynthetic tetracycline, minocycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and it has activity against a broad range of Gram-positive and Gram-negative organisms, including some multidrug-resistant strains. The program originated at Rempex Pharmaceuticals and was later advanced by The Medicines Company (subsequently Melinta Therapeutics’ anti-infective business), with clinical development including Phase I studies of the intravenous formulation in subjects with renal insufficiency.

Brand names

Minocin IV

Other names

Minocin for Injectionminocycline intravenousminocycline for injectionminocycline hydrochloride